PI3K/AKT/mTOR通路
雷氏菌
RPTOR公司
雷帕霉素的作用靶点
癌症研究
化学
索拉非尼
小型GTPase
细胞生物学
依维莫司
外体
基因敲除
调节器
肝细胞癌
激酶
TSC1
西罗莫司
生物
GTP酶
自噬
细胞生长
mTORC2型
刺猬信号通路
磷酸化
激活剂(遗传学)
清脆的
HEK 293细胞
细胞外
蛋白激酶结构域
胞浆
mTORC1型
细胞外小泡
内化
磷酸肌醇3激酶
作者
Ning Ma,Xiaoshan Xie,Yi-Xiang Wang,Zhikai Zheng,Huilin Jin,Xijie Chen,X M Huang,Haidan Luo,Yue Wei,Qihao Pan,Boyu Zhang,Jiaying Zheng,P P Zhang,Fenghai Yu,Xue Liu,Zhimin Zhang,Mong‐Hong Lee,Xiangqi Meng,Mong‐Hong Lee
摘要
Hepatocellular carcinoma (HCC) is associated with gut microbiota dysbiosis, yet specific oncogenic mechanisms remain elusive. We identified Enterococcus faecalis (EF) as significantly enriched in human liver tumours, where its abundance correlates with disease severity. Both live EF and its conditioned medium promoted HCC cell proliferation, protein translation and tumourigenesis. Mechanistically, EF-derived extracellular vesicles (EF-EVs) deliver the bacterial GTPase Obg to activate the host mTOR pathway and drive tumour progression. EF-Obg contains a Ras-like G domain homologous to the mTOR regulator Rheb and binds mTOR via a conserved G1 motif. CRISPR interference-mediated knockdown of obg in EF abolished mTOR activation and tumourigenic capacity in vivo. Clinically, high EF-Obg expression in HCC tissues correlates with mTOR hyperactivation and reduced patient survival. The mTOR inhibitor Everolimus effectively suppressed tumour growth in an EF-colonied orthotopic model, highlighting its therapeutic potential for HCC patients with high EF burden. Collectively, this work establishes a causal link between tumour-resident E. faecalis and hepatocarcinogenesis, revealing EF-Obg as a cross-kingdom activator of mTOR and providing a rationale for microbiota-guided personalised therapy in HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI